Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL507190 | 0.98 | PKLR (0.47) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL23432653 | 0.89 | TRIM24 (0.44) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL29546196 | 0.89 | TRIM24 (0.44) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL10163731 | 0.85 | CHRM2 (0.40) | PKLRPRKCIPKMMAPTHDAC3 | |
| SCHEMBL379048 | 0.84 | PRKCI (0.50) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL10280248 | 0.81 | PRKCI (0.47) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL11724375 | 0.81 | PRKCI (0.51) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL24783493 | 0.81 | PRKCI (0.47) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL3801450 | 0.80 | TAS1R3 (0.45) | PKLRPRKCIPKMMAPTCA12 | |
| SCHEMBL11821584 | 0.80 | PLK1 (0.51) | PKLRPRKCIPKMMAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016138-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024245310-A1 | THIAZOLYL OR THIADIAZOLYL AMIDES DERIVATIVES AND USE THEREOF | NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-113412112-B | Organophosphorus substituted compounds as c-MET inhibitors and therapeutic uses thereof | 贝达医药公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| WO-2022262657-A1 | N-SUBSTITUTED PHENYLSULFONAMIDE COMPOUND AND USE THEREOF | 上海璃道医药科技有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-21 | — | — | US | disclosed |
| CN-113412112-A | Organophosphorus substituted compounds as c-MET inhibitors and therapeutic uses thereof | 贝达医药公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1951707-A1 | SUBSTITUTED PYRROLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008022060-A2 | IMIDAZO-PYRIDINE DERIVATIVES FOR MODULATING PROTEIN KINASE ACTIVITY | NOVARTIS AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| EP-1818340-A1 | GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES | National University Corporation Nagoya University (JP) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007053657-A1 | SUBSTITUTED PYRROLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | PKLR 3193/4885PRKCI 1659/4885PKM 4089/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | PKLR 4411/4885PRKCI 2340/4885PKM 4446/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | PKLR 1043/4885PRKCI 2545/4885PKM 429/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | PKLR 4361/4885PRKCI 2386/4885PKM 4464/4885 |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | FOLR1, DHFR, TUBB3 | PKLR 1018/4885PRKCI 1205/4885PKM 1375/4885 |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | GCK, GCKR, PDXK | PKLR 187/4885PRKCI 337/4885PKM 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.